ProCE Banner Activity


Expanding Our Understanding of HER3 Expression, Implications, and Rationale for HER3-Targeted Therapy in Solid Tumors

Text Module

In this CME-certified text module with associated downloadable slideset, Misako Nagasaka, MD, PhD, reviews the role of HER3 in cancer biology and the rationale for targeting HER3 in the treatment of solid tumors.

Physicians: Maximum of 0.50 AMA PRA Category 1 Credit

Released: October 20, 2023

Expiration: October 19, 2024



Misako Nagasaka

Misako Nagasaka, MD, PhD

Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California Irvine School of Medicine
Orange, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner


Supported by an educational grant from Daiichi Sankyo, Inc.

Daiichi Sankyo, Inc.

Target Audience

This program is intended for medical oncologists and other healthcare professionals treating patients with NSCLC and breast cancer.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, and competence in using evidence-based and expert-recommended best practices in the care of patients with NSCLC and breast cancer.

Learning Objectives

Upon completion of this activity, participants should be able to: 

  • Evaluate the biology of HER3 overexpression and the rationale for targeting HER3 in the treatment of solid tumors


Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company. 

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity: 

Primary Author

Misako Nagasaka, MD, PhD

Associate Clinical Professor
Division of Hematology/Oncology
Department of Medicine
University of California Irvine School of Medicine
Orange, California

Misako Nagasaka, MD, PhD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Blueprint Medicine, Caris Life Sciences, Daiichi Sankyo, EMD Serono, Genentech, Janssen, Lilly, Mirati, Novartis, Pfizer, Regeneron, Serono, Takeda.

The planners and content peer reviewers from Clinical Care Options, LLC, do not have any relevant financial relationships to disclose. 

Instructions for Credit

Participation in this self-study activity should be completed in approximately 0.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from October 20, 2023, through October 19, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.


The program has been made available online. 

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 


Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 


Joint Accreditation Statement 

A logo for a companyDescription automatically generated with low confidenceIn support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. 


Physician Continuing Medical Education   
CCO designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit. Physicians should claim only the credit commensurate with the extent of their participation in the activity.